“…A total of 10203 patients diagnosed with various cancers, including laryngeal squamous cell carcinoma (LSCC) [ 22 ], ovarian cancer (OC) [ 23 ], renal cell carcinoma (RCC) [ 24 ], non-small cell lung cancer (NSCLC) [ 25 ], pancreatic cancer (PC) [ 26 – 29 ], colorectal cancer (CRC) [ 30 – 33 ], nasopharyngeal cancer (NPC) [ 21 , 34 – 36 ], gastric cancer (GC) [ 37 , 42 ], oral squamous cell carcinoma (OSCC) [ 38 ], hepatocellular carcinoma (HCC) [ 39 , 43 ], esophageal squamous cell carcinoma (ESCC) [ 40 , 41 ], small cell lung cancer (SCLC) [ 44 ], were included. These studies originated from China [ 21 – 24 , 27 , 28 , 33 – 36 , 39 – 42 , 44 ], Japan [ 26 , 30 – 32 , 37 , 43 ], and Korea [ 25 , 29 , 38 ], respectively. Twenty-three articles reported the outcomes of overall survival (OS) [ 21 – 31 , 33 – 44 ], and 6 studies presented disease free survival (DFS) as survival endpoint [ 22 , 24 , 26 , 32 , 34 , 37 ].…”